Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af en klinisk diagnostisk test for CRDS (DIAGNOSE CRDS)

4. november 2026 opdateret af: Population Health Research Institute

Evaluering af en klinisk diagnostisk test for Calcium Release Deficiency Syndrome: DIAGNOSE CRDS-undersøgelsen

Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Detaljeret beskrivelse

RyR2 loss-of-function variants have recently been established as causative for a new disease termed calcium release deficiency syndrome (CRDS) that confers a risk of malignant ventricular arrhythmias and sudden cardiac death. RyR2 encodes the cardiac ryanodine receptor, the calcium release channel on the sarcoplasmic reticulum that mediates excitation-contraction coupling through calcium-induced calcium-release. In contrast to CRDS, pathogenic RyR2 gain-of-function variants result in an autosomal dominant form of catecholaminergic polymorphic ventricular tachycardia (CPVT). The adrenergic-mediated ventricular arrhythmias characteristic of CPVT can be readily reproduced on exercise stress testing (EST), making EST the standard clinical diagnostic tool for CPVT.

In contrast to CPVT, the CRDS clinical phenotype is concealed with standard cardiac testing tools and its diagnosis presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. Beyond the significant time delay associated with in vitro functional analysis, this testing requires specialized expertise that is not widely available and remains research-based, making it impractical for routine use in clinical care. In this overall context, it is likely that the vast majority of global CRDS cases have yet to be diagnosed.

A prior report of an "atypical CPVT" family carrying an RyR2-p.M4109R variant observed marked and transient repolarization changes following pacing mediated tachycardia and a subsequent pause. Since publication of this report, in vitro characterization of the RyR2-p.M4109R variant has confirmed its being loss-of-function and the familial diagnosis has been revised to CRDS. Driven by these observations and promising preliminary findings, the DIAGNOSE CRDS study seeks to further investigate this apparent electrocardiographic signature of CRDS following brief tachycardia and subsequent pause as a potential method to clinically diagnose the condition.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

400

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Brussels, Belgien, 1090
        • Rekruttering
        • Universitair Ziekenhuis Brussel
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Luigi Pannone, MD
    • Antwerp
      • Edegem, Antwerp, Belgien, 2650
        • Rekruttering
        • Antwerp University Hospital
        • Ledende efterforsker:
          • Johan Saenen, MD, PhD
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
    • Alberta
      • Calgary, Alberta, Canada, T2N 1N4
        • Rekruttering
        • University of Calgary
        • Ledende efterforsker:
          • Erkan Ilhan, MD
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
      • Edmonton, Alberta, Canada, T6G 2C8
        • Rekruttering
        • Alberta Health Services
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Joseph Atallah, MD CM, MSc
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Rekruttering
        • The University of British Columbia
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Thomas M Roston, MD
      • Vancouver, British Columbia, Canada, V6H 3N1
        • Rekruttering
        • Children's & Women's Health Centre of British Columbia
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Shubhayan Sanatani, MD
    • Ontario
      • Hamilton, Ontario, Canada, L8L 2X2
        • Rekruttering
        • Hamilton General Hospital
        • Ledende efterforsker:
          • Jason D Roberts, MD MAS
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
      • London, Ontario, Canada, N6A 5A5
        • Rekruttering
        • London Health Sciences Centre - University Hospital
        • Ledende efterforsker:
          • Habib R Khan, MD
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
      • Ottawa, Ontario, Canada, K1Y 4W7
        • Rekruttering
        • Ottawa Heart Institute
        • Ledende efterforsker:
          • Simon Hansom, MD
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
      • Toronto, Ontario, Canada, M5G 2C4
        • Rekruttering
        • Toronto General Hospital
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Michael H. Gollob, MD, FRCP(C)
    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Rekruttering
        • Montréal Heart Institute
        • Ledende efterforsker:
          • Rafik Tadros, MD PhD
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
      • Québec, Quebec, Canada, G1V 4G5
        • Rekruttering
        • Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval
        • Ledende efterforsker:
          • Christian Steinberg, MD
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
      • Aarhus, Danmark, DK-8200 N
        • Rekruttering
        • Aarhus University Hospital
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Henrik Jensen, MD
    • London
      • London, London, Det Forenede Kongerige, WC1N 3JH
        • Rekruttering
        • Great Ormond Street Hospital
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Luke Starling, BSc (Hons), MB BS, FRCPCH
    • Oxfordshire
      • Oxford, Oxfordshire, Det Forenede Kongerige, OX3 9DU
        • Rekruttering
        • Oxford University Hospitals
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Julian Ormerod, BM, Bch, FRCP
    • California
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • University of California
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Vasanth Vedantham, MD, PhD
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Rekruttering
        • Boston Children's Hospital
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Dominic Abrams, MBBS, MD, MBA
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • John Giudicessi, MD, PhD
    • Washington
      • Seattle, Washington, Forenede Stater, 98195
        • Rekruttering
        • University of Washington
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Uyanga Batnyam, MD
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrig, 33404
        • Rekruttering
        • CHU de Bordeaux
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Frédéric Sacher, MD
      • Jerusalem, Israel, 9103102
        • Rekruttering
        • Shaare Zedek Medical Center
        • Kontakt:
          • Project Manager
          • Telefonnummer: 905-521-2100
          • E-mail: crds@phri.ca
        • Ledende efterforsker:
          • Ziv Dadon, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases

Inclusion criteria:

• Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing

Exclusion criteria:

• Unable to provide informed consent

Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases

Inclusion criteria:

  • Satisfy a clinical phenotype consistent with the Expert Consensus Statement
  • Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants

Exclusion criteria:

  • Unable to provide informed consent
  • Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers

Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA)

Inclusion criteria:

  • Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
  • Undergone genetic testing that includes screening of RyR2*

Exclusion criteria:

  • Unable to provide informed consent

  • Use of a QT prolonging medication at the time of the burst pacing maneuvers

    • Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary).

Cohort 4: SVT controls

Inclusion criteria:

• Undergoing an invasive electrophysiology study

Exclusion criteria:

  • Ventricular cardiomyopathy
  • Ventricular pre-excitation
  • Long QT syndrome
  • Use of a QT prolonging medication at the time of the EP study
  • Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study
  • Known obstructive coronary artery disease (existing coronary stenosis >50%)
  • Unable to provide informed consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Pacing

Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated.

  1. Ventricular 10 beat burst at 500ms (120bpm)
  2. Ventricular 10 beat burst at 400ms (150bpm)
  3. Atrial 10 beat burst at 500ms (120bpm)
  4. Atrial 10 beat burst at 400ms (150bpm).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
ΔT-wave amplitude value
Tidsramme: At time of pacing maneuver

T-wave amplitude on first post-pause sinus beat subtracted by the T-wave amplitude on the last sinus beat prior to pacing

At time of pacing maneuver
ΔQT value
Tidsramme: At time of pacing maneuver

Absolute QT value on first post-pause sinus beat subtracted by the absolute QT value on the last sinus beat prior to pacing

At time of pacing maneuver

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Absolute QT value
Tidsramme: At time of pacing maneuver

Absolute QT value on first post-pause sinus beat

At time of pacing maneuver
Absolute T-wave amplitude
Tidsramme: At time of pacing maneuver

Absolute T-wave amplitude on first post-pause sinus beat

At time of pacing maneuver

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Ziv Dadon, MD, Shaare Zedek Medical Center
  • Ledende efterforsker: Jason D Roberts, MD MAS, McMaster University
  • Ledende efterforsker: Wayne Chen, PhD, University of Calgary

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

2. februar 2023

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. marts 2028

Datoer for studieregistrering

Først indsendt

18. december 2023

Først indsendt, der opfyldte QC-kriterier

18. december 2023

Først opslået (Faktiske)

3. januar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner